114 related articles for article (PubMed ID: 10396079)
1. Induction of B cell autoimmunity by pristane.
Richards HB; Satoh M; Shaheen VM; Yoshida H; Reeves WH
Curr Top Microbiol Immunol; 1999; 246():387-92; discussion 393. PubMed ID: 10396079
[No Abstract] [Full Text] [Related]
2. Inhibition of pristane-induced peritoneal plasmacytoma formation.
Potter M; Kutkat L
Curr Top Microbiol Immunol; 1999; 246():351-61; discussion 361-2. PubMed ID: 10396075
[TBL] [Abstract][Full Text] [Related]
3. Perturbation of B cell genesis in the bone marrow of pristane-treated mice. Implications for plasmacytoma induction.
Rico-Vargas SA; Potter M; Osmond DG
J Immunol; 1995 Mar; 154(5):2082-91. PubMed ID: 7868885
[TBL] [Abstract][Full Text] [Related]
4. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.
Lattanzio G; Libert C; Aquilina M; Cappelletti M; Ciliberto G; Musiani P; Poli V
Am J Pathol; 1997 Sep; 151(3):689-96. PubMed ID: 9284817
[TBL] [Abstract][Full Text] [Related]
5. Indomethacin inhibition of pristane plasmacytomagenesis in genetically susceptible inbred mice.
Potter M
Adv Exp Med Biol; 1999; 469():151-6. PubMed ID: 10667324
[No Abstract] [Full Text] [Related]
6. Induction of plasma cell tumours with 2,6,10,14-tetramethylpentadecane (pristane) and paraffin oil (paraffinum perliquidum) in BALB/c mice simultaneously exposed to sustained antigenic stimulation with bovine serum albumin (BSA).
Janz S; Püschel W; Raabe F; Storch H
Arch Geschwulstforsch; 1987; 57(1):25-30. PubMed ID: 3566462
[TBL] [Abstract][Full Text] [Related]
7. Distinctive patterns of autoimmune response induced by different types of mineral oil.
Kuroda Y; Akaogi J; Nacionales DC; Wasdo SC; Szabo NJ; Reeves WH; Satoh M
Toxicol Sci; 2004 Apr; 78(2):222-8. PubMed ID: 14718649
[TBL] [Abstract][Full Text] [Related]
8. Influence of microbial stimulation on hypergammaglobulinemia and autoantibody production in pristane-induced lupus.
Hamilton KJ; Satoh M; Swartz J; Richards HB; Reeves WH
Clin Immunol Immunopathol; 1998 Mar; 86(3):271-9. PubMed ID: 9557160
[TBL] [Abstract][Full Text] [Related]
9. Disposition of the plasmacytomagenic alkane pristane (2,6,10,14-tetramethylpentadecane) in mice.
Janz S; Shacter E
Cancer Biochem Biophys; 1995 Jun; 15(1):25-34. PubMed ID: 8536217
[TBL] [Abstract][Full Text] [Related]
10. The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane.
Avcu F; Ural AU; Yilmaz MI; Ozcan A; Ide T; Kurt B; Yalcin A
Eur J Haematol; 2005 Jun; 74(6):496-500. PubMed ID: 15876253
[TBL] [Abstract][Full Text] [Related]
11. In vitro mutagenicity of the plasmacytomagenic agent pristane (2,6,10,14-tetramethylpentadecane).
Felix K; Potter M; Bornkamm GW; Janz S
Cancer Lett; 1997 Feb; 113(1-2):71-6. PubMed ID: 9065804
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens.
Potter M; Wax JS
J Natl Cancer Inst; 1983 Aug; 71(2):391-5. PubMed ID: 6576197
[TBL] [Abstract][Full Text] [Related]
13. The fluidity of DOPC bilayers and membrane fractions prepared from murine plasmacytoma cells is unchanged after incorporation of pristane (2,6,10,14-tetramethylpentadecane) as assessed by fluorescence polarization analysis.
Janz S; Krumbiegel M; Gawrisch K
Cancer Biochem Biophys; 1992 Nov; 13(2):85-92. PubMed ID: 1343851
[TBL] [Abstract][Full Text] [Related]
14. Elevated mutant frequencies in lymphoid tissues persist throughout plasmacytoma development in BALB/c.lambdaLIZ mice.
Felix K; Kelliher KA; Bornkamm GW; Janz S
Cancer Res; 1999 Aug; 59(15):3621-6. PubMed ID: 10446972
[TBL] [Abstract][Full Text] [Related]
15. Gas chromatographic-mass spectrometric investigation of four commercial pristane (2.6.10.14-tetramethylpentadecane) preparations used for plasmacytoma induction in BALB/c mice.
Janz S; Birkenfeld T; Herzschuh R; Storch H
Arch Geschwulstforsch; 1989; 59(6):415-22. PubMed ID: 2596957
[TBL] [Abstract][Full Text] [Related]
16. Differential susceptibility of BALB/c and DBA/2 cells to plasmacytoma induction in reciprocal chimeras.
Silva S; Sugiyama H; Babonits M; Wiener F; Klein G
Int J Cancer; 1991 Sep; 49(2):224-8. PubMed ID: 1879968
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors.
Clynes R; Calvani N; Croker BP; Richards HB
Clin Exp Immunol; 2005 Aug; 141(2):230-7. PubMed ID: 15996187
[TBL] [Abstract][Full Text] [Related]
18. Nephritogenic autoantibodies but absence of nephritis in Il-12p35-deficient mice with pristane-induced lupus.
Calvani N; Satoh M; Croker BP; Reeves WH; Richards HB
Kidney Int; 2003 Sep; 64(3):897-905. PubMed ID: 12911539
[TBL] [Abstract][Full Text] [Related]
19. Generation of immunoglobulin/c-myc recombinations in murine Peyer's patch follicles.
Müller JR; Mushinski EB; Jones GM; Williams JA; Janz S; Hausner PF; Potter M
Curr Top Microbiol Immunol; 1997; 224():251-5. PubMed ID: 9308248
[No Abstract] [Full Text] [Related]
20. Detection of immunoglobulin/c-myc recombinations in mice that are resistant to plasmacytoma induction.
Müller JR; Jones GM; Potter M; Janz S
Cancer Res; 1996 Jan; 56(2):419-23. PubMed ID: 8542601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
